Psoriasis vulgaris flare during efalizumab therapy does not preclude future use: a case series

Psoriasis vulgaris flare during efalizumab therapy does not preclude future use: a case series

BACKGROUND Severe psoriasis vulgaris can be extremely difficult to treat in some patients, even with the newer biological therapies available today. CASE PRESENTATIONS We present two patients with severe chronic plaque psoriasis who received numerous systemic anti-psoriatic therapies with varied results. Both responded well to initial treatment with efalizumab (anti-CD11a), but then experienc...

Psoriasis vulgaris flare during efalizumab therapy does not preclude future use : Case

Eruptive papules during efalizumab (anti-CD11a) therapy of psoriasis vulgaris: a case series

BACKGROUND Newer biological therapies for moderate-to-severe psoriasis are being used more frequently, but unexpected effects may occur. CASE PRESENTATIONS We present a group of 15 patients who developed inflammatory papules while on efalizumab therapy (Raptiva, Genentech Inc, anti-CD11a). Immunohistochemistry showed that there were increased CD11b+, CD11c+ and iNOS+ cells (myeloid leukocytes...

Exacerbation of psoriasis under efalizumab therapy.

BACKGROUND Efalizumab is a recombinant humanized IgG1-kappa isotype monoclonal antibody that binds to CD11a, inhibiting T-cell activation. It has been approved for the treatment of moderate to severe plaque psoriasis. Efalizumab has been associated with the development of skin eruptions during the administration period, and this probably represents the potential psoriasis events observed during...

Use of Standard Form Does Not Preclude TILA Violation